Ma Teng, Zhao Jian, Yan Yechao, Liu Junying, Zang Jie, Zhang Yaqi, Ruan Kun, Xu Hong, He Wan
Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Emergency Department, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Front Cardiovasc Med. 2023 Jun 14;10:1178153. doi: 10.3389/fcvm.2023.1178153. eCollection 2023.
Osteoprotegerin (OPG) is a secretory glycoprotein and participates in the progression of atherosclerotic lesions. We aim to explore the relationship between OPG and the prognosis of coronary artery disease (CAD).
Plasma OPG concentrations were measured in 3,766 patients with stable CAD enrolled in the PEACE trial. The PEACE trial (NCT00000558) group followed up the patients and examined their future clinical outcomes.
In summary, 208 (5.5%) primary outcomes occurred, 295 patients (7.8%) died from all-cause death, 128 (3.4%) died from cardiovascular causes, and 94 (2.5%) experienced heart failure during a median follow-up of 1,892 days. In addition, we found that higher plasma levels of OPG were associated with a higher incidence of all-cause death, cardiovascular death, and heart failure, even after adjusting clinical cofounders.
It was demonstrated that elevated plasma OPG levels were associated with an increased incidence of all-cause death, cardiovascular death, and heart failure in patients with stable CAD.
https://clinicaltrials.gov/ct2/show/NCT00000558?term=NCT00000558&draw=2&rank=1, identifier: NCT00000558.
骨保护素（OPG）是一种分泌性糖蛋白，参与动脉粥样硬化病变的进展。我们旨在探讨OPG与冠状动脉疾病（CAD）预后之间的关系。
在参加PEACE试验的3766例稳定型CAD患者中测量血浆OPG浓度。PEACE试验（NCT00000558）组对患者进行随访，并检查他们未来的临床结局。
总之，在中位随访1892天期间，发生了208例（5.5%）主要结局，295例患者（7.8%）死于全因死亡，128例（3.4%）死于心血管原因，94例（2.5%）发生心力衰竭。此外，我们发现，即使在调整临床混杂因素后，较高的血浆OPG水平与全因死亡、心血管死亡和心力衰竭的发生率较高相关。
结果表明，稳定型CAD患者血浆OPG水平升高与全因死亡、心血管死亡和心力衰竭的发生率增加相关。
https://clinicaltrials.gov/ct2/show/NCT00000558?term=NCT00000558&draw=2&rank=1，标识符：NCT00000558。
